Literature DB >> 16146041

Vascular endothelial growth factor (VEGF) in physiological and pathological conditions.

Grazyna Chodorowska1, Janusz Chodorowski, Andrzej Wysokiński.   

Abstract

Vascular endothelial growth factor (VEGF) is the major endothelial-cell specific stimulatory factor regarded as the most important positive regulator of angiogenesis and vascular permeability. Due to its powerful angiogenic and mitogenic properties, VEGF takes part in a variety of crucial biological processes, including wound repair and tumorigenesis. The elevated expression of VEGF and its receptors has been found in malignancies of various origin as being associated with metastasis formation and poor prognosis. Recently, some possibilities appeared to block the VEGF action when it is undesirable or promote its activity when it can be useful. These new therapeutic strategies based upon the knowledge of VEGF biological role, are being tried and up till now they proved to be successful, especially in anticancer therapy and the coronary heart disease treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16146041

Source DB:  PubMed          Journal:  Ann Univ Mariae Curie Sklodowska Med        ISSN: 0066-2240


  3 in total

1.  Regulation of hypoxic response elements on the expression of vascular endothelial growth factor gene transfected to rat skeletal myoblasts under hypoxic environment.

Authors:  Lei Xu; Jiahong Xia; Kailun Zhang; Aini Xie
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-10-10

2.  Pioglitazone does not increase the risk of type II diabetes in patients with bladder cancer: A retrospective study.

Authors:  Youhong Dong; Anping Wang
Journal:  Oncol Lett       Date:  2016-05-13       Impact factor: 2.967

3.  Drynaria fortunei Promoted Angiogenesis Associated With Modified MMP-2/TIMP-2 Balance and Activation of VEGF Ligand/Receptors Expression.

Authors:  Sheng-Teng Huang; Cheng-Chieh Chang; Jong-Hwei S Pang; Hung-Sen Huang; Shen-Chieh Chou; Ming-Ching Kao; Huey-Ling You
Journal:  Front Pharmacol       Date:  2018-09-21       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.